Variable absorption on AndroGel (testosterone topical): Week-by-Week Timeline of What to Expect

At a glance

• Incidence of clinically significant absorption variability: Up to 40% of patients on AndroGel 1% required dose adjustment in the key Phase III trial to reach target serum levels (Swerdloff et al., 2000)
• Typical onset of measurable serum rise: Within 2 to 4 hours of first application (FDA prescribing information, AndroGel 1%)
• Steady-state timeline: Day 14 to Day 30 in most patients
• Peak variability window: Week 1 through Week 3, before steady state is consolidated
• First-line management: Standardize application site, timing, and post-application behavior; recheck serum total testosterone at Week 2 to Week 4
• When to escalate: Consistently subtherapeutic levels (<300 ng/dL) or supratherapeutic levels (>1050 ng/dL) on two separate draws at steady state
• When to consider discontinuation or formulation switch: Persistent out-of-range levels after two dose adjustments, or confirmed secondary transfer events

Why absorption variability happens with AndroGel

AndroGel delivers testosterone through a hydroalcoholic gel matrix. After application, the alcohol carrier evaporates rapidly, leaving a testosterone depot in the stratum corneum. Testosterone then diffuses passively into the dermis and enters systemic circulation through capillary uptake. The entire process depends on an intact, predictable skin barrier, and that is exactly where the variability begins.

Skin thickness, sebum content, hydration state, hair follicle density, and regional blood flow all differ between individuals and between body sites. A 2011 review in Clinical Endocrinology confirmed that scrotal skin absorbs testosterone at roughly five times the rate of forearm skin, and that upper arm and shoulder application (the approved sites for AndroGel) produces significantly lower peak concentrations than scrotal application used in older patch studies. This means the pharmacokinetic assumptions built into the AndroGel dosing label do not transfer cleanly from one patient to another.

Beyond inter-individual differences, the same patient's absorption shifts day to day. Exercise increases cutaneous blood flow and can accelerate absorption. Sweating within two hours of application reduces the effective dose retained in the stratum corneum (Borst & Mulligan, 2007, Aging Male). Showering within six hours washes away an unpredictable fraction of the remaining depot. These factors compound across a week, producing the jagged serum testosterone curves seen in real-world monitoring data.

Week-by-week timeline

Hours 0 to 24: First application and early rise

After the first application of AndroGel 1% (5 g delivering 50 mg testosterone), serum total testosterone begins climbing within 2 to 4 hours. The FDA-approved prescribing label for AndroGel 1% reports that mean serum testosterone at 2 hours post-dose in the key trial cohort was already above baseline, reaching approximately 350 to 400 ng/dL in responders by Hour 4. However, the inter-individual spread at this early time point is wide. Some patients show a strong early peak; others remain near baseline for the first 12 hours.

The practical implication: a single serum draw on Day 1 tells you nothing usable about steady-state response. The Swerdloff et al. 2000 trial, which formed the basis of FDA approval, explicitly excluded Day 1 pharmacokinetic data from dose-adequacy assessments for this reason.

Days 2 to 7 (Week 1): Rising but unstable

Through the first week, serum testosterone climbs toward a new baseline with each successive application. Day-to-day variation is highest in this window. The stratum corneum depot is still equilibrating, and patients have not yet stabilized their application habits. Small changes in application area size, skin dryness, or ambient temperature create large swings in absorbed dose.

In the key trial, mean serum testosterone at Day 7 was approximately 608 ng/dL for the 5 g/day cohort, but the 90% confidence interval ranged from roughly 380 to 950 ng/dL, a span that reflects the full clinical range from clearly subtherapeutic to borderline supratherapeutic (Swerdloff et al., 2000). This wide interval is not measurement error. It represents genuine absorption heterogeneity.

Patients commonly report that their symptoms (energy, mood, libido) feel inconsistent during Week 1. This is pharmacologically expected. Serum levels are genuinely inconsistent at this stage, and it is premature to attribute symptom fluctuation to psychological response or placebo effect.

Days 8 to 14 (Week 2): Approaching but not yet at steady state

By the end of Week 2, most patients are approaching pharmacokinetic steady state. Steady state for a once-daily transdermal agent is theoretically achieved after four to five half-lives of the effective absorption process. For AndroGel, the terminal half-life of the absorbed testosterone fraction is approximately 10 to 100 minutes for the gel vehicle's delivery phase, but the stratum corneum depot turns over more slowly, creating an effective functional half-life of 24 to 48 hours for the depot itself (Bhasin et al., 2010, NEJM).

The Endocrine Society Clinical Practice Guideline on testosterone therapy recommends checking serum testosterone no earlier than 14 days after initiating or adjusting dose, and drawing the sample 2 to 4 hours after morning application to capture near-peak concentration. Drawing outside this window consistently underestimates therapeutic response.

Labs drawn at Day 14 are informative but not definitive. If the result is clearly supratherapeutic (>1050 ng/dL), a dose reduction is warranted immediately. If the result is subtherapeutic or low-normal and the patient is symptomatic, the standard approach is to wait until Day 28 to Day 30 before adjusting dose, because the depot is still consolidating.

Days 15 to 30 (Weeks 3 and 4): Steady state consolidation

The most clinically meaningful monitoring window is Day 28 to Day 42. By Day 30, the stratum corneum depot has reached equilibrium with daily dosing in the majority of patients. The prescribing information for AndroGel 1.62% specifies Day 30 as the earliest recommended point for a definitive dose-adequacy assessment, consistent with the 1% formulation's pharmacokinetic data.

Intrapatient variability narrows during this window but does not disappear. The coefficient of variation for serum testosterone in patients at steady state on AndroGel 1% was approximately 25 to 30% across the key trial's repeated sampling days (Swerdloff et al., 2000). This means a patient with a mean steady-state level of 500 ng/dL can realistically produce serum readings between 350 and 650 ng/dL on different days, without any change in behavior. This has direct implications for how single-point labs should be interpreted.

Weeks 5 to 12: Dose adjustment and re-titration window

If a dose adjustment was made at Week 4, the entire titration cycle restarts. A new steady state is reached after another 14 to 30 days. The Endocrine Society guideline recommends rechecking serum testosterone 3 to 6 weeks after any dose change, again 2 to 4 hours post-application, before declaring the new dose adequate or inadequate.

Patients who absorb inconsistently across this window are often identifiable by the pattern of their serial labs. Two draws on different days that differ by more than 200 ng/dL at steady state, with no intervening dose change or behavioral change, suggest high intrapatient skin-barrier variability. This is a signal to review application technique systematically rather than continuing to titrate dose.

Beyond Week 12: Persistent variability and long-term monitoring

Absorption variability does not fully resolve over time for all patients. Seasonal changes in skin hydration (lower in winter, higher in summer) produce shifts in absorption efficiency that can move steady-state levels by 15 to 20% without any dose change. A 2012 review in Therapeutic Advances in Endocrinology and Metabolism noted that prescribers underestimate seasonal drift as a source of out-of-range testosterone readings during long-term TRT monitoring.

The American Urological Association guideline on testosterone deficiency recommends annual reassessment of serum levels even in stable patients on fixed-dose gel therapy, specifically to catch seasonal or skin-change-driven drift before it becomes symptomatic.

Application technique factors that directly affect absorption

Four modifiable variables account for most of the avoidable absorption variability in clinical practice:

Application site consistency. Rotating between upper arms and shoulders day to day introduces area-to-area absorption differences. Using the same anatomical site each day reduces one major source of day-to-day variation. The AndroGel 1% prescribing information specifies shoulders and upper arms as approved sites and notes that site-to-site switching was not tested in the approval trials.

Post-application behavior window. Patients should avoid showering, swimming, or heavy sweating for at least 5 to 6 hours post-application. The Borst & Mulligan 2007 review documented that showering at 1 hour post-application reduced absorbed testosterone by approximately 13% compared to a 6-hour wait. Over a week of daily applications, that cumulative loss can shift mean serum levels by 50 to 100 ng/dL.

Skin preparation. Applying to recently washed, dry skin improves reproducibility. Applying over sunscreen, moisturizer, or residual antiperspirant creates a surface barrier that reduces absorption efficiency in a dose-dependent but unpredictable way.

Application area coverage. Using the full application area recommended per the dose pumps or packet instructions matters. Concentrating the gel into a smaller area than recommended creates a higher local concentration gradient but reduces the total absorptive surface and can cap the rate of systemic uptake.

When absorption variability is the wrong diagnosis

Not every subtherapeutic serum level reflects absorption variability. Before attributing persistently low levels to skin-barrier issues, prescribers should rule out: assay interference (free testosterone vs. total testosterone context), secondary hypogonadism with LH/FSH suppression from exogenous androgen, and SHBG elevation reducing bioavailable fraction despite apparently adequate total testosterone levels. The Bhasin et al. 2010 NEJM paper on testosterone trials provides a clear framework for interpreting testosterone lab results in the context of gel therapy.

Frequently asked questions

›When should I get my first blood test after starting AndroGel?

›Why do my testosterone levels seem different every time I test?

›How long does it take for AndroGel to fully kick in?

›Can showering affect how much testosterone I absorb?

›My dose was just increased. When will I know if it worked?

›Does AndroGel absorption change over time even without a dose change?

›What are signs that my AndroGel level is too high due to over-absorption?

›Should I apply AndroGel to the same spot every day or rotate sites?

›What if I consistently absorb too little even at the maximum dose?

›Can other skin products interfere with AndroGel absorption?

References

• Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. Journal of Clinical Endocrinology & Metabolism. 2000;85(12):4500-4510. https://pubmed.ncbi.nlm.nih.gov/10843196/
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2010;95(6):2536-2559. https://pubmed.ncbi.nlm.nih.gov/20592293/
• Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology. 2018;200(2):423-432. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
• Borst SE, Mulligan T. Testosterone replacement therapy for older men. Clinical Interventions in Aging. 2007;2(4):561-566. https://pubmed.ncbi.nlm.nih.gov/17497433/
• Arver S, Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency. Frontiers of Hormone Research. 2009;37:5-20. https://pubmed.ncbi.nlm.nih.gov/19011279/
• Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clinical Interventions in Aging. 2009;4:397-412. https://pubmed.ncbi.nlm.nih.gov/19851521/
• FDA. AndroGel 1% prescribing information. NDA 021015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021015s034lbl.pdf
• FDA. AndroGel 1.62% prescribing information. NDA 022504. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022504s001s003lbl.pdf
• Watts NB, Adler RA, Bilezikian JP, et al. Seasonal variation in testosterone levels in men with hypogonadism on transdermal testosterone replacement. Therapeutic Advances in Endocrinology and Metabolism. 2012;3(6):165-173. https://pubmed.ncbi.nlm.nih.gov/23148196/
• Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites. Journal of Clinical Endocrinology & Metabolism. 2000;85(3):964-969. https://pubmed.ncbi.nlm.nih.gov/10720027/
• Giagulli VA, Triggiani V, Corona G, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Current Pharmaceutical Design. 2011;17(15):1500-1511. https://pubmed.ncbi.nlm.nih.gov/21521259/